Scalper1 News
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped 75% over the year-earlier quarter to $3.49 a share, topping analysts’ consensus by 25 cents, according to Thomson Reuters. Sales gained 40% to $2.66 billion, beating estimates by about $70 million. As in Scalper1 News
Scalper1 News